company background image

OK Biotech TWSE:4155 Stock Report

Last Price


Market Cap







25 Sep, 2022


Company Financials
4155 fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance4/6
Financial Health6/6

4155 Stock Overview

OK Biotech Co., Ltd. manufactures and sells blood glucose meters worldwide.

OK Biotech Competitors

Price History & Performance

Summary of all time highs, changes and price drops for OK Biotech
Historical stock prices
Current Share PriceNT$26.15
52 Week HighNT$26.95
52 Week LowNT$22.10
1 Month Change9.41%
3 Month Change8.96%
1 Year Change13.70%
3 Year Change-22.06%
5 Year Change-26.97%
Change since IPO71.71%

Recent News & Updates

Shareholder Returns

4155TW Medical EquipmentTW Market

Return vs Industry: 4155 exceeded the TW Medical Equipment industry which returned -8.9% over the past year.

Return vs Market: 4155 exceeded the TW Market which returned -17.6% over the past year.

Price Volatility

Is 4155's price volatile compared to industry and market?
4155 volatility
4155 Average Weekly Movement3.0%
Medical Equipment Industry Average Movement5.5%
Market Average Movement5.0%
10% most volatile stocks in TW Market8.2%
10% least volatile stocks in TW Market2.4%

Stable Share Price: 4155 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 4155's weekly volatility (3%) has been stable over the past year.

About the Company


OK Biotech Co., Ltd. manufactures and sells blood glucose meters worldwide. It also provides nebulizers, glucometers, blood sugar meters, blood glucose test strips, and personal sound amplifiers. The company was founded in 2006 and is headquartered in Hsinchu City, Taiwan.

OK Biotech Fundamentals Summary

How do OK Biotech's earnings and revenue compare to its market cap?
4155 fundamental statistics
Market CapNT$2.48b
Earnings (TTM)NT$116.34m
Revenue (TTM)NT$1.52b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
4155 income statement (TTM)
Cost of RevenueNT$1.22b
Gross ProfitNT$299.14m
Other ExpensesNT$182.80m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)1.23
Gross Margin19.68%
Net Profit Margin7.65%
Debt/Equity Ratio35.3%

How did 4155 perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio
We’ve recently updated our valuation analysis.


Is 4155 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 1/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4155?

Other financial metrics that can be useful for relative valuation.

4155 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.6x
Enterprise Value/EBITDA19.6x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 4155's PE Ratio compare to its peers?

4155 PE Ratio vs Peers
The above table shows the PE ratio for 4155 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average32.7x
4129 United Orthopedic
1786 SciVision Biotech
6612 ICARES Medicus
3373 Radiant Innovation
4155 OK Biotech

Price-To-Earnings vs Peers: 4155 is good value based on its Price-To-Earnings Ratio (21.3x) compared to the peer average (32.7x).

Price to Earnings Ratio vs Industry

How does 4155's PE Ratio compare vs other companies in the TW Medical Equipment Industry?

Price-To-Earnings vs Industry: 4155 is expensive based on its Price-To-Earnings Ratio (21.3x) compared to the TW Medical Equipment industry average (20.5x)

Price to Earnings Ratio vs Fair Ratio

What is 4155's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4155 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.3x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 4155's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of 4155 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4155 (NT$26.15) is trading above our estimate of fair value (NT$14.87)

Significantly Below Fair Value: 4155 is trading above our estimate of fair value.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is OK Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OK Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

Past Performance

How has OK Biotech performed over the past 5 years?

Past Performance Score


Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 4155 has high quality earnings.

Growing Profit Margin: 4155's current net profit margins (7.7%) are higher than last year (6.6%).

Past Earnings Growth Analysis

Earnings Trend: 4155's earnings have declined by 8.1% per year over the past 5 years.

Accelerating Growth: 4155's earnings growth over the past year (26.9%) exceeds its 5-year average (-8.1% per year).

Earnings vs Industry: 4155 earnings growth over the past year (26.9%) exceeded the Medical Equipment industry 19%.

Return on Equity

High ROE: 4155's Return on Equity (6.2%) is considered low.

Discover strong past performing companies

Financial Health

How is OK Biotech's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 4155's short term assets (NT$1.6B) exceed its short term liabilities (NT$790.1M).

Long Term Liabilities: 4155's short term assets (NT$1.6B) exceed its long term liabilities (NT$402.8M).

Debt to Equity History and Analysis

Debt Level: 4155's net debt to equity ratio (0.6%) is considered satisfactory.

Reducing Debt: 4155's debt to equity ratio has reduced from 44.5% to 35.3% over the past 5 years.

Debt Coverage: 4155's debt is well covered by operating cash flow (21.5%).

Interest Coverage: 4155's interest payments on its debt are well covered by EBIT (8x coverage).

Balance Sheet

Discover healthy companies


What is OK Biotech current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 3/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 4155's dividend (3.82%) is higher than the bottom 25% of dividend payers in the TW market (2.46%).

High Dividend: 4155's dividend (3.82%) is low compared to the top 25% of dividend payers in the TW market (6.73%).

Stability and Growth of Payments

Stable Dividend: 4155's dividend payments have been volatile in the past 10 years.

Growing Dividend: 4155's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: At its current payout ratio (81%), 4155's payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (209%), 4155's dividend payments are not well covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


OK Biotech has no CEO, or we have no data on them.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 1 shareholders own 0.48% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Dimensional Fund Advisors LP
458,843NT$12.0m0.19%no data

Company Information

OK Biotech Co., Ltd.'s employee growth, exchange listings and data sources

Key Information

  • Name: OK Biotech Co., Ltd.
  • Ticker: 4155
  • Exchange: TWSE
  • Founded: 2006
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Implied Market Cap: NT$2.483b
  • Shares outstanding: 94.93m
  • Website:


  • OK Biotech Co., Ltd.
  • No. 91, Gongdao 5th Road
  • Sec. 2
  • Hsinchu City
  • 30070
  • Taiwan


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4155TWSE (Taiwan Stock Exchange)YesCommon StockTWTWDDec 2010

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/25 00:00
End of Day Share Price2022/09/23 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.